M. Gutniak < M. Guttman < M. Haap

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 21.
[0-20] [0 - 20][0 - 21][20-20][20-40]

Ident.	Authors (with country if any)	Title
001069 (2007)	M. Guttman [Canada] ; I. Boileau ; J. Warsh ; J A Saint-Cyr ; N. Ginovart ; T. Mccluskey ; S. Houle ; A. Wilson ; E. Mundo ; P. Rusjan ; J. Meyer ; S J Kish	Brain serotonin transporter binding in non-depressed patients with Parkinson's disease.
001351 (2003)	D. Coyle [Canada] ; M. Barbeau ; M. Guttman ; J-F Baladi	The economic evaluation of pharmacotherapies for Parkinson's disease.
001439 (2002)	M. Guttman [Canada] ; P M Slaughter ; M E Theriault ; D P Deboer ; C D Naylor	Parkinsonism in Ontario: physician utilization.
001490 (2001)	M. Guttman [Canada] ; J. Jaskolka	The use of pramipexole in Parkinson's disease: are its actions D(3) mediated?
001500 (2001)	M. Guttman [Canada] ; P M Slaughter ; M E Theriault ; D P Deboer ; C D Naylor	Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study.
001512 (2001)	M. Guttman [Canada] ; D. Stewart ; D. Hussey ; A. Wilson ; S. Houle ; S. Kish	Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.
001631 (1999)	M. Guttman [Canada] ; O. Suchowersky	Parkinson's disease management: towards a new paradigm.
001727 (1997)	M. Guttman [Canada] ; J. Burkholder ; S J Kish ; D. Hussey ; A. Wilson ; J. Dasilva ; S. Houle	[11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold.
001767 (1997)	M. Guttman [Canada]	Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
001812 (1996)	J M Wilson [Canada] ; A I Levey ; A. Rajput ; L. Ang ; M. Guttman ; K. Shannak ; H B Niznik ; O. Hornykiewicz ; C. Pifl ; S J Kish	Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease.
001834 (1995)	H. Kuwabara [Canada] ; P. Cumming ; Y. Yasuhara ; G C Léger ; M. Guttman ; M. Diksic ; A C Evans ; A. Gjedde	Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
001916 (1993)	A. Gjedde [Canada] ; G C Léger ; P. Cumming ; Y. Yasuhara ; A C Evans ; M. Guttman ; H. Kuwabara	Striatal L-dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis.
001953 (1993)	M. Guttman [Canada] ; G. Léger ; A. Reches ; A. Evans ; H. Kuwabara ; J M Cedarbaum ; A. Gjedde	Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
001954 (1993)	H. Hoshi [Canada] ; H. Kuwabara ; G. Léger ; P. Cumming ; M. Guttman ; A. Gjedde	6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.
001994 (1992)	M. Guttman [Canada]	Dopamine receptors in Parkinson's disease.
001A03 (1992)	R F Peppard [Canada] ; W R Martin ; G D Carr ; E. Grochowski ; M. Schulzer ; M. Guttman ; P L Mcgeer ; A G Phillips ; J K Tsui ; D B Calne	Cerebral glucose metabolism in Parkinson's disease with and without dementia.
001A87 (1990)	M. Guttman [Canada] ; H C Fibiger ; A. Jakubovic ; D B Calne	Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism.
001B15 (1989)	V W Yong [Canada] ; M. Guttman ; S U Kim ; D B Calne ; I. Turnbull ; K. Watabe ; R W Tomlinson	Transplantation of human sympathetic neurons and adrenal chromaffin cells into parkinsonian monkeys: no reversal of clinical symptoms.
001B31 (1989)	M. Guttman [Canada] ; R S Burns ; W R Martin ; R F Peppard ; M J Adam ; T J Ruth ; G. Allen ; R A Parker ; N B Tulipan ; D B Calne	PET studies of parkinsonian patients treated with autologous adrenal implants.
001B86 (1988)	M. Guttman [Canada] ; V W Yong ; S U Kim ; D B Calne ; W R Martin ; M J Adam ; T J Ruth	Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys.
001B91 (1988)	E C Wolters [Canada] ; J C Kebabian ; M. Guttman ; E. Mak ; B D Pate ; D B Calne	A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/Author.i -k "M. Guttman" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/Author.i  \
                -Sk "M. Guttman" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Author.i
   |clé=    M. Guttman
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022